Hence, we propose a new experimental outline based on model, (1) consisting of miR-34a as an inhibitor of the E2F1/Myc pathway (main inducers of ANRIL/UFC1), which can block cancer progression and modulate apoptosis and senescence. The gene discussed is CDKN2B-AS1; the disease is cancer.